Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction

Phase 3

Completed

Conditions: Acute Coronary Syndromes

Interventions: Drug: Clopidogrel (SR25990)
Drug: Placebo

First Posted Date: 2008-07-14

Last Posted Date: 2009-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 3491

Registration Number: NCT00714961

Locations: 🇿🇦
sanofi-aventis South Africa, Midrand, South Africa
🇵🇱
sanofi-aventis Poland, Warszawa, Poland
🇧🇪
sanofi-aventis Belgium, Diegem, Belgium

and more 13 locations

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility

Phase 3

Terminated

Conditions: Venous Thromboembolism

Interventions: Drug: Semuloparin sodium
Drug: Enoxaparin sodium

First Posted Date: 2008-07-14

Last Posted Date: 2013-01-23

Lead Sponsor: Sanofi

Target Recruit Count: 421

Registration Number: NCT00714597

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
🇦🇺
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Lixisenatide (AVE0010)
Drug: Placebo
Device: Pen auto-injector
Drug: Sulfonylurea
Drug: Metformin

First Posted Date: 2008-07-14

Last Posted Date: 2016-12-14

Lead Sponsor: Sanofi

Target Recruit Count: 859

Registration Number: NCT00713830

Locations: 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Lixisenatide (AVE0010)
Drug: Placebo
Device: Pen auto-injector
Drug: Metformin

First Posted Date: 2008-07-10

Last Posted Date: 2016-12-15

Lead Sponsor: Sanofi

Target Recruit Count: 680

Registration Number: NCT00712673

Locations: 🇦🇺
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, Australia
🇻🇪
Sanofi-Aventis Administrative Office, Caracas, Venezuela